ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
NovaBay Pharmaceuticals Inc New

NovaBay Pharmaceuticals Inc New (NBY)

0.65
-0.05
(-7.14%)
마감 09 2월 6:00AM
0.6446
-0.0054
(-0.83%)
시간외 거래: 9:31AM

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

주요 통계 및 세부정보

가격
0.6446
매수가
-
매도가
-
거래량
45,782
0.6501 일간 변동폭 0.6801
0.3611 52주 범위 9.079
market_cap
전일 종가
0.70
개장가
0.68
최근 거래 시간
301
@
0.65
마지막 거래 시간
재정 규모
US$ 31,005
VWAP
0.677242
평균 볼륨(3m)
249,572
발행 주식
4,885,693
배당수익률
-
주가수익률
-0.20
주당순이익(EPS)
-3.42
매출
14.73M
순이익
-16.7M

NovaBay Pharmaceuticals Inc New 정보

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare and skincare products. Its leading product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have broad antimicrobial... NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare and skincare products. Its leading product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
본부
Wilmington, Delaware, USA
설립됨
-
NovaBay Pharmaceuticals Inc New is listed in the Pharmaceutical Preparations sector of the 아메리카 증권거래소 with ticker NBY. The last closing price for NovaBay Pharmaceuticals was US$0.70. Over the last year, NovaBay Pharmaceuticals shares have traded in a share price range of US$ 0.3611 to US$ 9.079.

NovaBay Pharmaceuticals currently has 4,885,693 shares in issue. The market capitalisation of NovaBay Pharmaceuticals is US$3.42 million. NovaBay Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.20.

NBY 최신 뉴스

NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal

Stockholders voted to unlock the value of NovaBay’s Avenova® eyecare business by approving the $11.5 million asset sale Reconvened Special Meeting adjourned to allow additional time for votes to...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.01362.155309033280.6310.7000010.5994929300.66793049CS
40.02053.284730011220.62410.8350.54998040.70380267CS
12-0.0954-12.89189189190.740.8350.492495720.66174419CS
260.160733.20934077290.48391.00990.361115796900.71584245CS
52-4.0489-86.26611270914.69359.0790.361133542543.74984961CS
156-403.6054-99.8405442177404.25442.2250.3611168770635.97487841CS
260-686.5804-99.906202481687.2252670.50.36112137357672.63380338CS

NBY - Frequently Asked Questions (FAQ)

What is the current NovaBay Pharmaceuticals share price?
The current share price of NovaBay Pharmaceuticals is US$ 0.6446
How many NovaBay Pharmaceuticals shares are in issue?
NovaBay Pharmaceuticals has 4,885,693 shares in issue
What is the market cap of NovaBay Pharmaceuticals?
The market capitalisation of NovaBay Pharmaceuticals is USD 3.42M
What is the 1 year trading range for NovaBay Pharmaceuticals share price?
NovaBay Pharmaceuticals has traded in the range of US$ 0.3611 to US$ 9.079 during the past year
What is the PE ratio of NovaBay Pharmaceuticals?
The price to earnings ratio of NovaBay Pharmaceuticals is -0.2
What is the cash to sales ratio of NovaBay Pharmaceuticals?
The cash to sales ratio of NovaBay Pharmaceuticals is 0.23
What is the reporting currency for NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals reports financial results in USD
What is the latest annual turnover for NovaBay Pharmaceuticals?
The latest annual turnover of NovaBay Pharmaceuticals is USD 14.73M
What is the latest annual profit for NovaBay Pharmaceuticals?
The latest annual profit of NovaBay Pharmaceuticals is USD -16.7M
What is the registered address of NovaBay Pharmaceuticals?
The registered address for NovaBay Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the NovaBay Pharmaceuticals website address?
The website address for NovaBay Pharmaceuticals is www.novabay.com
Which industry sector does NovaBay Pharmaceuticals operate in?
NovaBay Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
LIAEStone Ridge 2050 Inflation-Protected Longevity Income ETF
US$ 173.096
(900.00%)
2
LFAIStone Ridge 2050 Longevity Income ETF
US$ 132.05
(900.00%)
3
LFAEStone Ridge 2048 Longevity Income ETF
US$ 121.596
(900.00%)
21
LIACStone Ridge 2049 Inflation-Protected Longevity Income ETF
US$ 164.999
(900.00%)
10
LFAFStone Ridge 2049 Longevity Income ETF
US$ 126.796
(900.00%)
7
CHROChannel Therapeutics Corporation
US$ 1.28
(-18.99%)
131.39k
AZTRAzitra Inc
US$ 0.3418
(-11.52%)
2.89M
CLDICalidi Biotherapeutics Inc
US$ 1.3099
(-11.49%)
2.36M
MPUMega Matrix Inc
US$ 0.8549
(-11.01%)
204.14k
SCPXScorpius Holdings Inc
US$ 0.2198
(-10.50%)
670.78k
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 26.33
(-4.91%)
87.91M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
US$ 5.8796
(2.97%)
80.97M
FXIiShares China Large Cap
US$ 32.735
(1.41%)
73.25M
TSLZT Rex 2X Inverse Tesla Daily Target ETF
US$ 2.85
(7.14%)
67.49M
ETHU2x Ether ETF
US$ 4.083
(-10.26%)
53.99M

NBY Discussion

게시물 보기
glenn1919 glenn1919 4 주 전
NBY...................................https://stockcharts.com/h-sc/ui?s=NBY&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 주 전
NBY.............................https://stockcharts.com/h-sc/ui?s=NBY&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 4 주 전
NBY news .77 + 20%

....On January 3, 2025, NovaBay Pharmaceuticals, Inc. (the “Company”) entered into a Trademark Acquisition Agreement, (the “Trademark Acquisition Agreement”), by and between the Company and Phase One Health LLC, a Tennessee limited liability company (“Phase One”), that provides for the purchase by Phase One of the Company’s wound care product trademarks NeutroPhase, PhaseOne and OmniPhase (collectively, the “Trademarks”), for a purchase price of $500,000 (the “Wound Care Transaction”). In connection with the Wound Care Transaction, the Company also entered into a Transition Services Agreement, dated January 3, 2025, by and between the Company and Phase One (the “Transition Services Agreement”), pursuant to which the Company will: (i) provide limited transition services to Phase One until January 10, 2025; (ii) sell the Company’s existing wound care inventory from an outstanding purchase order (the “Inventory”) to Phase One for an aggregate payment of $126,000; and (iii) provide its remaining empty wound care product bottles to Phase One. In addition, the Transition Services Agreement provides that the existing supplier and distributor relationship between the Company and PhaseOne will be terminated upon the closing of the Wound Care Transaction.
 
As previously disclosed, the Company entered into a separate agreement to sell the Company’s eyecare products under the Avenova brand and related assets, which represents substantially all of the assets of the Company, pursuant to the Asset Purchase Agreement dated September 19, 2024, by and between the Company and PRN Physician Recommended Nutriceuticals, LLC, a Delaware limited liability company (“PRN”), as amended on November 5, 2024 by that certain Amendment No. 1 to Asset Purchase Agreement (the “Asset Sale Transaction”), which remains subject to stockholder approval. The Trademarks sold pursuant to the Trademark Acquisition Agreement and the Inventory sold pursuant to the Transition Services Agreement were assets of the Company’s wound care business that were excluded from the Asset Sale Transaction.
 
Additional information regarding the Asset Sale Transaction is included in the Current Reports on Form 8-K that were filed by the Company with the Securities and Exchange Commission (the “SEC”) on September 20, 2024 and November 6, 2024 and in the Company’s definitive proxy statement on Schedule 14A for the Special Meeting filed with the SEC on October 16, 2024 (the “Special Meeting Proxy Statement”), as supplemented from time to time, including by the supplement to the Special Meeting Proxy Statement dated as of November 12, 2024 (the “Proxy Supplement”).
 
The Trademark Acquisition Agreement contains representations, warranties and agreements of the parties that are customary for a transaction of this nature. The Company also agreed to provide limited indemnification to Phase One under the Trademark Acquisition Agreement for losses arising from a third-party claim involving a material breach or nonperformance of representations, warranties, covenants, agreements and obligations of the Company contained in the Trademark Acquisition Agreement. The Company’s liability for any such losses is limited to 50% of the purchase price for the Trademarks.
 
The foregoing description of the Trademark Acquisition Agreement and the Transition Services Agreement contains only a brief description of the material terms and does not purport to be a complete description of the rights and obligations of the parties to the Trademark Acquisition Agreement and the Transition Services Agreement, and such description is qualified in its entirety by reference to the full text of the Trademark Acquisition Agreement and the Transition Services Agreement, copies of which are filed as Exhibits 2.1 and 10.1 to this Current Report on Form 8-K and incorporated herein by reference....
 
👍️0
MasterBlastr MasterBlastr 3 월 전
It looks like they are going to dissolve the company and sell off the assets. Sound like a Chap 7. Wonder if there will be anything left for the shareholders.
👍️0
toddski toddski 3 월 전
Completely incompetent management. Could never turn a profit, so let's sell. The brand, pay off debts / management, and give stockholders a few pennies for their trouble. Management makes and break companies. And these guys are breakers. 
👍️0
glenn1919 glenn1919 3 월 전
NBY..................................https://stockcharts.com/h-sc/ui?s=NBY&p=W&b=5&g=0&id=p86431144783
👍️0
Triple nickle Triple nickle 5 월 전
Quietly rising
👍️0
Triple nickle Triple nickle 5 월 전
Added more
👍️0
da_stock_analyst da_stock_analyst 5 월 전
#NBY 🔥 big gap upside! can it break $1 and move 50% another up? $NBY
👍️0
Triple nickle Triple nickle 5 월 전
Back to .77
👍️0
tw0122 tw0122 5 월 전
NBY 1.02 + 102% still going energizer bunny
👍️0
tw0122 tw0122 5 월 전
BLUE BELL, Pa., Sept. 20, 2024 /PRNewswire/ -- Acumen Health Holdings, LLC, a professionally recommended, consumer-preferred dietary supplements company focused on eye health and companion animals, announced today that its subsidiary, PRN Physician Recommended Nutriceuticals, LLC, has entered into a definitive asset purchase agreement to acquire the assets of the Avenova® brand (the "Brand") and business from NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay"). The Brand offers several products for ocular health including cleansing sprays, absorbent wipes, and heated eye masks. The Brand's leading product, the Avenova® Lid & Lash Cleansing Spray, is a hypochlorous acid spray utilized to promote eye hygiene. Avenova® products are sold through the direct-to-consumer, professional, and retail pharmacy channels. The transaction is anticipated to close in the fourth quarter of 2024, subject to the satisfaction of customary closing conditions.

Acumen Health Holdings

The acquisition of the Brand will bolster PRN's existing portfolio and strengthen PRN's commitment to deliver high-quality products that have a meaningful impact on patients' eye health. PRN will leverage their existing sales force and relationships with optometrists and ophthalmologists to expand access and awareness of Avenova® products.

"The Brand pioneered the use of hypochlorous acid in eyecare and has a long history of success in the professional channel," said Scott Woodruff, CEO of Acumen Health Holdings. "This exciting acquisition broadens PRN's existing eye health product portfolio and allows PRN to better serve patients through offering an expanded suite of science-based eye health products."

The deal builds on PRN's strategy to grow its presence in the eye health market organically and through acquisitions. Avenova® will represent the sixth add-on acquisition completed by PRN in the past 5 years.

Please see the NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) press release for information regarding their go-forward plans following this transaction.

Alex Putala
(920) 255-4972
960 Harvest Drive, Suite B250
Blue Bell, PA 19422

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/acumen-health-holdings-acumen-to-acquire-the-avenova-brand-from-novabay-pharmaceuticals-302253803.html

SOURCE Acumen Health Holdings

👍️0
tw0122 tw0122 5 월 전
Pump me up
👍️0
budgetthis budgetthis 6 월 전
A couple Pennie’s a day keeps the bill collectors away……lol.

$$ NBY $$
👍️0
budgetthis budgetthis 6 월 전
Looks like good old NovaBay is reawakening……how nice !

$$ NBY $$
👍️0
budgetthis budgetthis 6 월 전
Up, up and away ??

👍️0
Monksdream Monksdream 6 월 전
NBY new 52 week low
👍️0
MasterBlastr MasterBlastr 6 월 전
Why? Because you think it stopped dropping?
👍️0
budgetthis budgetthis 6 월 전
Looks like the time to buy is upon us ?

👍️0
Monksdream Monksdream 6 월 전
NBY new 52 week low
👍️0
Monksdream Monksdream 6 월 전
NBY new 52 week low
👍️0
MasterBlastr MasterBlastr 6 월 전
You were right about the no brain part. Shareholders destroyed.
👍️0
Monksdream Monksdream 6 월 전
NBY new 52 week low
👍️0
budgetthis budgetthis 7 월 전
No brainer continued gainer, in my modest opinion !!

$$ NBY $$
👍️0
elks elks 7 월 전
When
👍️0
elks elks 7 월 전
Wow
👍️0
Termite7 Termite7 8 월 전
So, I shouldn't buy? ....Thanks!!!
👍️0
RammageRaul RammageRaul 8 월 전
I was gonna buy today this is why I dont like to hold this thing overnight LOL
👍️0
jonner jonner 8 월 전
Thank you for mentioning RS. I was about to load up. Maybe I will after the 30th.
👍️0
BIOCHEMUP BIOCHEMUP 8 월 전
RS
👍️0
BIOCHEMUP BIOCHEMUP 8 월 전
See you in post market for the spike!
👍️0
BIOCHEMUP BIOCHEMUP 9 월 전
Go NBY go.
👍️0
Lottoplay Lottoplay 9 월 전
$NBY send it!
👍️0
Lottoplay Lottoplay 9 월 전
$NBY all we need is a little bit of news and this should skyrocket! Let’s go!
👍️0
Lottoplay Lottoplay 9 월 전
now they’re toying with us.
👍️0
Lottoplay Lottoplay 9 월 전
$NBY they’re holding it down, let her rip!!!
👍️0
NewBreedd NewBreedd 9 월 전
Looking like the next $1.00+ runner
👍️0
glenn1919 glenn1919 9 월 전
NBY..........................................https://stockcharts.com/h-sc/ui?s=NBY&p=W&b=5&g=0&id=p86431144783
👍️0
TheFinalCD TheFinalCD 9 월 전
$NBY

https://finviz.com/quote.ashx?t=NBY&ty=c&ta=1&p=d

https://dilutiontracker.com/app/search/NBY?a=dbb88c
👍️0
akamaii akamaii 9 월 전
Yes
👍️0
BIOCHEMUP BIOCHEMUP 9 월 전
Looks yummy
👍️0
Lottoplay Lottoplay 9 월 전
Good entry point here?
👍️0
The Night Stalker The Night Stalker 9 월 전
cheap
👍️0
The Night Stalker The Night Stalker 9 월 전
cheap
👍️0
CarlCarlMcB CarlCarlMcB 10 월 전
Fish on $$$$$$ start reeling $$$$$$$$$
👍️0
Fredric Fredric 10 월 전
News out... trading up...good potential here today
👍️0
Money hunt Money hunt 11 월 전
Blue Skies coming$$$$$$$$
👍️0
Money hunt Money hunt 11 월 전
Watch and see what happens when this blasts through.157
👍️0
Money hunt Money hunt 11 월 전
Sound all alarms!!!! tsunami warning!!!!
👍️0
Money hunt Money hunt 11 월 전
Here’s the dip!!! To the mooooooooon!!!!
👍️0

최근 히스토리

Delayed Upgrade Clock